The FDA is soliciting comments from stakeholders on its Health Care Professional Survey of Professional Prescription Drug Promotion.

The survey aims to gauge healthcare professionals’ opinions on promotional materials and procedures targeted at them, as well as their knowledge of abuse-deterrent formulations for opioids. Drugmakers spent more than $24 billion in physician marketing in 2012.

The survey seeks to identify the methods used to disseminate promotional information, how knowledgeable HCPs are about clinical trial data and its connection to promotional material.